Obsidian Therapeutics (Nasdaq: OBX) announced the enrollment of the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE